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dium change and had mesenchymal features but failed dif-
ferentiation assays.  Discussion: Routine in vitro expansion of 
AF-derived mesenchymal cells remains problematic. De-
spite an increase in successful cell cultures from 40 up to 80% 
using optimized serum and an increased cell density, even-
tually cells failed to demonstrate differentiation abilities. 
Routine isolation and expansion from unselected AF sam-
ples remains a challenge.  © 2013 S. Karger AG, Basel 
 Introduction 
 Mesenchymal stem cells (MSC) were first isolated from 
adult bone marrow  [1, 2] and later from a variety of other 
organs. The potential of MSC to differentiate into osteo-
blasts, chondrocytes, adipocytes, myoblasts, neural cells, 
and stromal fibroblasts  [3–7] and their apparently low im-
munogenicity after allogenic transfer make MSC a very 
attractive cell type for tissue repair and regeneration and 
other cell therapy applications  [8–10] . MSC, in particular 
those derived from bone marrow, are already widely used 
clinically. They are an adjuvant to reestablish the hemato-
poietic system following radiation and/or chemotherapy, 
stimulating engraftment and preventing graft-versus-
host disease  [11, 12] . Coronary artery infusion of autolo-
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 Abstract 
 Background: Amniotic fluid (AF) cell populations will be ap-
plied in perinatology. We aimed to test the feasibility of 
large-scale cell expansion.  Study Methods: We determined 
the best out of three published expansion protocols for mes-
enchymal progenitors (AF samples, n = 4) in terms of self-
renewal ability. Characterization was performed based on 
morphology, surface marker analysis, cytogenetic stability, 
and differentiation potential. The conditions for the best 
self-renewal ability were further determined in a consecu-
tive series (n = 159).  Results: The medium containing fetal 
bovine serum (FBS), epidermal growth factor, insulin, trans-
ferrin, and tri-iodothyronine, combined with seeding on gel-
atin-coated wells, best stimulated the growth of cells with 
mesenchymal features, as demonstrated by flow cytometry; 
however, only osteogenic differentiation was possible. 
Large-scale testing (n = 44) failed to confirm a robust self-
renewal ability. Better results were obtained (n = 88) using 
optimized FBS or an increased initial cell density. Eventually 
over 81% of cultures continued growing after the initial me-
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gous bone marrow-derived MSC improved cardiac func-
tion 3 months after cardiac infarction  [13] . The ability of 
MSC to differentiate into neurons and astrocytes led to 
their use in the treatment of symptomatic ALS  [14] . Injec-
tion of allogenic MSC has been shown to slow down the 
typical degradation process of lysosomal storage diseases 
 [15] . MSC are also proposed as excellent candidate cell 
sources for tissue engineering biomaterials  [16] .
 MSC also appear attractive in fetal or perinatal medi-
cine  [16, 17] . MSC isolated from first-trimester fetal 
blood have already been used as an allogenic graft for the 
treatment of children with osteogenesis imperfecta and 
significantly reduce bone brittleness  [18, 19] . MSC de-
rived from umbilical cord vessels have the ability to mi-
grate in vitro towards areas of alveolar type II cell damage 
and to assist in cell repair probably through paracrine ef-
fects  [20] . Another potential application is the transduc-
tion of MSC by a variety of vectors for their use as vehicles 
for either short- or long-term gene transfer  [16] . Further, 
they could be used in tissue engineering applications for 
the treatment of congenital birth defects, for instance to 
provide alternative cell-seeded matrices to replace syn-
thetic materials required for reconstruction of the defect 
 [21, 22] . Experimentally, the proof of principle for this 
has already been provided  [23–25] .
 In other words, the fetus may be considered as a host 
who is treated after birth with autologous tissue-engi-
neered prostheses, or as a donor, providing the cellular 
components to process the biomaterials required after 
birth  [21] . Several fetal tissues, including liver, bone mar-
row, lung, and pancreas, have been shown to contain cells 
with MSC characteristics, plastic properties, and a re-
markable self-renewal ability  [26] . Several cell types with 
self-renewal abilities, multilineage differentiation poten-
tial, and mesenchymal features have been successfully 
isolated from the fetal adnexa (membranes, placenta, and 
cord)  [20, 27–30] . Since 2007, these cells have been clas-
sified using the consensus established by an international 
workshop  [31] . Unfortunately, these cells only become 
spontaneously available at the time of birth, limiting their 
availability and applications for autologous treatments. 
However, amniotic fluid (AF) can also be retrieved pre-
natally with an acceptable risk, allowing successful isola-
tion of this type of cells  [32] . Amniocentesis is indeed of-
fered in patients with structural defects to rule out genet-
ic problems or to measure certain metabolites that 
correlate with the severity of the disease involved. In se-
lected cases, one might consider harvesting a certain 
amount of additional AF which could be used for extract-
ing cells. These can then be further cultured and manipu-
lated in vitro during the remainder of pregnancy. Either 
during pregnancy or, more often, after birth, these cells 
might be used to treat the fetus or neonate  [33] .
 Several methods for isolation of MSC have been de-
scribed. They are based on selection of cells based on their 
physical characteristics (e.g. spindle shaped, fibroblast-
like aspect) or adherence properties to plastic  [29, 34, 35] 
or to other extracellular matrix components  [27, 36] . Also 
various media have been used to culture and expand MSC 
 [27, 29, 35, 36] . In this study we aimed to select an appro-
priate medium and culture conditions to isolate and ex-
pand cells with mesenchymal features and self-renewal 
and differentiation abilities derived from AF in a routine 
clinical setting.
 Materials and Methods 
 Culture of Cells Derived from AF 
 Small-Scale Comparison of Three Culture Conditions 
 We initially selected 4 AF samples of male fetuses obtained dur-
ing different types of fetoscopic procedures. Three AF samples 
were collected during laser coagulation of placental vessels in twin-
twin transfusion syndrome at a mean gestational age (GA) of 19 ± 
3 weeks. One sample was obtained at the time of fetal endoscopic 
tracheal occlusion (FETO) for a severe diaphragmatic hernia at 29 
weeks and 4 days of gestation. Samples had a confirmed normal 
karyotype, their starting volume exceeded 20 ml, and the bacterio-
logic examination was negative. AF samples were centrifuged for 
5 min at 400  g. Cells were plated in 6-well plates (Nunc, Roskilde, 
Denmark) and cultured on polystyrene only or fibronectin (100 ng/
ml; Sigma, Bornem, Belgium) or gelatin-coated wells (Sigma) and 
using the following 3 media which were previously used for grow-
ing human AF-derived MSC  [27, 28] , amnion mesenchymal cells 
 [37], and bone marrow-derived multipotent progenitor cells  [36] :
 – medium 1: M199 (Gibco, Merelbeke, Belgium) supplemented 
with 10% fetal bovine serum (FBS; Stem Cell Technologies, 
Grenoble, France), 20 μg/ml endothelial cell growth factor 
(ECGF; Roche Diagnostics, Vilvoorde, Belgium), and 8 U/ml 
heparin (Sigma); 
 – medium 2: DMEM-H/Ham’s F12 1: 1 (Sigma) supplemented 
with 10% FBS, 50 ng/ml epidermal growth factor (EGF), 2.5 μg/
ml insulin, 5 μg/ml transferrin, and 0.1 ng/ml tri-iodothyronin 
(T3) (all from Sigma); 
 – medium 3: 60% DMEM (Gibco), 40% MCDM-201 (Sigma) 
supplemented with 2% FBS, 1× insulin-transferrin-selenium 
(Sigma), 1× chemically defined lipid concentration (Gibco), 
10 ng/ml platelet-derived growth factor (PDGF; R&D, Abing-
don, UK), 10 ng/ml EGF, 25 μg/ml  L -ascorbic acid (Sigma), and 
0.5 nmol/ml dexamethasone (Sigma). 
 After 4–5 days, nonadherent cells were removed and the media 
refreshed. When grown to subconfluence, adherent cells were de-
tached with 0.25% trypsin-EDTA (Sigma), manually counted, and 
replated at 10 3 cells/cm 2 in culture flasks (T25 and T75; Falcon, 
Erembodegem-Aalst, Belgium). This point in time was considered 
as passage 0 (P0).
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 Human synovial-derived MSC were obtained from the syno-
vial membrane (SM) of healthy adults as described previously  [38] 
and cultured as control stem cells in DMEM (Gibco) supplement-
ed with 10% FBS. All media were supplemented with 100 U/ml 
penicillin and 100 μg/ml streptomycin (Invitrogen, Merelbeke, 
Belgium) and replaced every 2–3 days. All cells were cultured in 
duplicate in a 95% humidified atmosphere at 37   °   C and 5% CO 2 . 
Self-renewal ability was evaluated through the calculation of cell 
doublings [formula: log (number of cells at time 1/number of cells 
at time 0)/log2] and the population doubling time [formula: (time 
0 – time 1) × log2/log (number of cells at T1/number of cells at T0)] 
to determine the protocol yielding the best cell self-renewal ability.
 Large-Scale (n = 159) Prospective Validation 
 The optimal culture condition was further used on a larger 
scale. During the course of the experiments, further attempts were 
made to increase the efficacy, such as using an optimized FBS or 
seeding an initial higher cell number, as detailed in Results. In to-
tal, 159 consecutive AF samples were obtained during routine clin-
ical procedures, such as genetic amniocentesis (n = 86) and feto-
scopic interventions for complicated monochorionic twin preg-
nancies (n = 44) and FETO procedures (n = 29). The mean GA for 
amniocentesis were 16.9 ± 0.3 weeks, 19.4 ± 1.5 weeks for laser 
coagulation, and 28.8 ± 1.2 weeks for fetuses undergoing FETO. 
These samples will be hereafter referred to as ‘prospective sam-
ples’. The primary outcome measure was again self-renewal ability. 
AF-MSC were characterized after >20 cell doublings by morphol-
ogy and FACS analysis and differentiation potential by immuno- 
and cytochemical staining. Cytogenetic stability was determined 
by karyotyping at prelevation and after >20 cell doublings. This 
characterization time point was determined to allow enough cell 
expansion for all of the required assays. 
 Flow Cytometric Analysis 
 After a second trypsinization (this was considered as passage 1; 
P1), cells were washed with phosphate-buffered saline (PBS; Gib-
co) containing 0.1% bovine serum albumin (BSA; Sigma). The cells 
cultured from the initial samples used for the culture condition 
comparison were incubated with fluorescein isothiocyanate 
(FITC)-, phycoerythrin (PE)-, or allophycocyanin (APC)-conju-
gated antibodies for 30 min at 4  °  C or room temperature according 
to the manufacturer’s instructions. Cells were analyzed using a 
Becton-Dickinson (BD, Erembodegem-Aalst, Belgium) 3-channel 
flow cytometer and quantification was performed using BD FACS 
Diva software.
 For the prospective validation study, cells were analyzed using 
a BD 2-channel flow cytometer with FITC- and PE-conjugated 
antibodies.  Quantification was performed using BD FACS Diva 
software. 
 We selected different surface markers based on a review of the 
literature  [28, 29, 39] . The following antibodies against MSC mark-
ers were used: CD166 (Acris, Herford, Germany), CD105 (R&D), 
CD73 (BD), CD44 (BD), and CD29 (Biosource, Nivelles,  Belgium). 
As hematopoietic stem cell markers we used: CD14 (Biosource), 
CD34 (BD), and CD45 (R&D). Antibodies against immunologic 
markers were: HLA-ABC (MHC I; BD) and HLA-DR (MHC II; 
BD). Unlabeled cells were used as negative controls and isotype 
control antibodies to quantify nonspecific binding. 7-Aminoacti-
nomycin D (7-AAD, 1: 100; BD) was added to all samples in order 
to exclude autofluorescence of dead cells.
 Differentiation Ability 
 In vitro Osteogenesis 
 AF-derived cells as well as SM-derived MSC were replated 
at 2 × 10 4 cells/cm 2 . Osteogenesis was induced with DMEM me-
dium (10% FBS) supplemented with 10 μmol/l dexamethasone, 
10  nmol/l 1α,25-dihydroxy-vitamin D 3 , 50 μg/ml ascorbic acid, 
and 10 mmol/l β-glycerophosphate (all from Sigma). For each 
sample, unstimulated cells were used as controls.  Alizarin red S 
staining was performed to identify calcified matrix. After fixing the 
cells in ice-cold 70% ethanol (Fluka, Bornem, Belgium), calcium 
precipitates were stained with 2% Alizarin red S (Sigma) in PBS. 
Matrix mineralization was demonstrated by the presence of a red 
deposition.
 In vitro Adipogenesis 
 AF-derived cells as well as SM-derived MSC were replated at 
2 × 10 4 cells/cm 2 . Adipogenic differentiation was initiated using 
DMEM medium (10% FBS) supplemented with 0.5 mmol/l isobu-
tyl-methylxanthine (IBMX), 1 μmol/l dexamethasone, 200 μmol/l 
indomethacin (all from Sigma), and 10 μmol/l insulin (Novo Nor-
disk, Brussels, Belgium). Oil red staining was performed to iden-
tify cytoplasmic lipid droplet accumulation. Cells were fixed with 
ice-cold methanol (Fluka) and washed with deionized water. Sam-
ples were stained with 0.5% (w/v in isopropanol) Oil red O (Sigma) 
and counterstained with Mayer’s Hematoxylin (Fluka).
 Karyotyping by G-Banding Analysis 
 Initial karyotyping was performed on cells from fresh AF, and 
later cells from cultures after 20 cell doublings were karyotyped to 
demonstrate cytogenetic stability.
 Statistics and Ethical Considerations 
 Results are presented as means ± SEM. Statistical analysis was 
performed using Fisher’s exact test, the Mann-Whitney U test, and 
the Kruskal-Wallis test with Statistica for Windows XP. p < 0.05 
was considered statistically significant. This project was approved 
by the Ethics Committee for Clinical Studies of the University of 
Leuven, Belgium, and informed consent was obtained for each pa-
tient. 
 Results 
 Comparison of Culture Conditions 
 Cell Morphology 
 At the time of the first seeding, the attached AF-de-
rived cells displayed heterogeneous sizes and morphol-
ogy, with small cobblestone-like cells, larger irregular 
cells, and spindle-shaped cells. When the medium was 
refreshed 5–7 days after the first seeding, and nonadher-
ent cells were removed, a majority of spindle-shaped 
cells were observed, with this phenotype becoming ex-
clusive around confluence ( fig.  1 a). By around 10–15 
population doublings, medium 1 on uncoated or fibro-
nectin-coated wells, as well as medium 3, irrespective of 
the coating type, eventually yielded cells that could not 
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be further used in the experiment. Cells became broader 
and more flattened and ceased to replicate beyond 
4 weeks and/or underwent cell death ( fig. 1 b). More pre-
cisely, this was after 97 ± 5 days and 10 ± 2 cell doublings 
(medium 1, fibronectin) and 14 ± 1 cell doublings (me-
dium 1, uncoated) or 15 ± 1 cell doublings (medium 3, 
gelatin), 10 ± 2 cell doublings (medium 3, fibronectin), 
and 13 ± 1 cell doublings (medium 3, uncoated). These 
cells were not further sorted or tested for differentia-
tion  or karyotyped. After 20 cell doublings, cells cul-
tured with medium 2 lost their spindle-shaped form 
( fig. 1 c, d).
 Cell Growth Kinetics 
 Overall, cell proliferation was faster when using me-
dium 2 compared to either of the other two media, irre-
spective of the coating used ( fig.  2 a–c). Cell doublings 
with medium 2 on the 3 different coatings were compa-
rable [33 ± 2 (gelatin), 30 ± 2 (fibronectin), and 28 ± 1 
(uncoated), respectively; p > 0.05] at a mean of 128 ± 
7 days. There were no differences in the overall cell dou-
bling time (gelatin: 66 ± 7 h, fibronectin: 66 ± 5 h; un-
coated: 87 ± 13 h; p > 0.05). When compared with me-
dium 2 on gelatin, cells cultured in medium 1 on gelatin-
coated wells displayed higher cell doubling times (82 ± 
6 h, p < 0.001) and lower cell doubling numbers (26 ± 2 
cell doublings, p = 0.005) compared to cells cultured in 
medium 2 on gelatin (66 ± 7 h and 33 ± 2 cell doublings, 
respectively). Interestingly, the mean cell doubling time 
for cells cultured in medium 2 was 40–60 h for the initial 
20 cell doublings, and it increased to  ≥ 94 h thereafter 
( t able 1 ). A similar trend was found for cells seeded on 
gelatin and cultured in medium 1. 
 Flow Cytometry 
 As a control, 3 cultures of SM-derived MSC were used. 
Cases were AF-derived cells cultured in medium 1 and 
plated on gelatin (n = 8), or cultured in medium 2 and 
plated on gelatin (n = 6), fibronectin (n = 5), or uncoated 
wells (n = 6). They were characterized at a mean cell dou-
bling of 21 ± 1. Flow cytometry analysis of all AF-derived 
cells stained positive for the MSC markers CD29, CD44, 
CD73, CD105, and CD166, but was negative for the he-
matopoietic stem cell markers CD14, CD34, and CD45 
( fig. 3 ). The surface marker expression pattern was simi-
lar to the profile of human SM-derived MSC ( fig.  4 ). 
However, SM-derived MSC cultures showed a signifi-
cantly higher percentage of cells expressing CD105 and 
CD166 compared to AF-derived cells ( fig. 4 ; p < 0.05). All 
AF-derived MSC expressed HLA-ABC (MHC I) but not 
HLA-DR (MHC II). This was also the case for SM-de-
rived MSC, but more cells stained positive for MHC II 
a b
c d
 Fig. 1. AF-derived cells seeded on polysty-
rene with medium 2 shown  at 12 popula-
tion doublings (mainly spindle-shaped 
cells and few larger and flat cells) ( a ). When 
cultured in medium 3 on polystyrene, these 
cells (at 16 population doublings) were 
broader and flatter ( b ). After 28 cell dou-
blings, AF-derived cells cultured on poly-
styrene in medium 2 became flatter ( c ) and 
showed more dying cells ( d ). Magnifica-
tion ×200. 
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(p < 0.05). Comparing the results of the cases, AF-derived 
MSC cultured on gelatin in medium 1 had significantly 
more CD29+ cells (p = 0.005) than those cultured in me-
dium 2, irrespective of the coating. 
 Differentiation Ability 
 The numbers of cell doublings prior to differentiation 
were comparable. In vitro adipo- and osteogenesis were 
evaluated. Osteogenic differentiation was effective ( fig. 5 ). 
After stimulation with an osteogenic medium, SM-de-
rived MSC showed a higher percentage of calcified cell 
matrices compared to AF-derived MSC seeded on gelatin 
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Table 1.  Cell doubling times categorized by cell doublings and ac-
cording to the media and coating used
 Cell doubling times (mean ± SEM), h
mediu m 1 medium 2
Cell 
doublings
gelatin gelatin fibronectin polystyrene
≤20 71±5 40±2 50±3 59±11
>20 115±17 97±12 94±8 147±29
Fig. 2. Comparison of cell doublings over time, dependent on the 
medium and coating of culture flasks used.  a  Medium 1.  b Me-
dium 2.  c Medium 3.  d FBS vs. O-FBS. When using medium 2, the 
highest cell doubling number and fastest proliferation were ob-
tained. Squares and black lines represent results for coating with 
gelatin, circles and dashed lines represent fibronectin, and trian-
gles and grey lines represent polystyrene (no coating). The differ-
ence with the other two media disappeared after 130 days ( a–c ). 
Comparison of cell doublings over time using medium 2 with ei-
ther FBS (circles and lower line) or optimized FBS (triangles and 
upper line). Higher cumulative cell doublings were observed with 
O-FBS ( d ).
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in medium 1 (p < 0.05) but comparable calcification rates 
in relation to AF-derived MSC cultured in medium 2 in 
wells coated with gelatin or fibronectin or left uncoated 
(p > 0.05). Differentiation of AF-derived MSC into adi-
pocytes was not successful.
 Karyotype Using G-Banding Analysis 
 Cytogenetic analysis of AF cells prior to culture and 
from cultures using medium 1 or 2 on gelatin, fibronec-
tin, or polystyrene showed a normal male karyotype after 
21 ± 2 cell doublings.
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Fig. 3. Representative flow cytometry surface marker profile of AF-derived cells. Dark grey represents positively labeled cells for the 
given markers, and light grey represents the isotype controls. 
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 Routine Expansion of Cells with Mesenchymal 
Features from Prospective AF Samples 
 Cell Morphology and Growth Kinetics 
 Based on the information presented above, medium 2 
on gelatin-coated well plates was further used to culture 
prospective AF samples. In an initial 44 samples, spindle-
shaped cells were now growing in only 29.5% (n = 13) of 
cases. In the other 70.5% (n = 31), when the medium was 
refreshed at 5–7 days and nonadherent cells were re-
moved, an absence of cell growth with a majority of larg-
er irregular cells was observed. In the remainder, where 
spindle-shaped cells were growing until subconfluence, 
those eventually became broader and more flattened and 
ceased to replicate after trypsinization and reseeding in 
53.8% of cases (n = 7). In 6 samples where cells continued 
to grow, the mean cumulative cell doubling was 12.1 ± 
1.7, with a mean cell doubling time of 171.5 ± 22.6 h. This 
low number of growing cells, combined with a very low 
self-renewal ability, were judged to be an insufficient re-
sult and an obstacle for further cell characterization and 
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white represents hematopoietic markers, and black represents immunologic markers. 
Fig. 5. Representative example of AF-de-
rived cells isolated with medium 2. Cells 
were thereafter cultured at P1, after osteo-
genic stimulation. Alizarin red S stain 
shows calcified extracellular matrix ( a ). As 
a reference, unstimulated cells were stained 
in the same conditions ( b ). Magnification 
×200. 
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differentiation. For that reason, we questioned whether 
the medium used was consistently identical. Upon de-
tailed revision, one component of the medium was FBS 
which, during the course of the experiments, originated 
from different lots. FBS batch differences have been rec-
ognized as a cause of discrepant results  [40] . Actually, a 
better self-renewal ability has been reported when one 
uses FBS that is optimized for expansion of human MSC 
(O-FBS)  [28, 34] .
 From that point on, we prospectively compared 88 
cultures with the initially used FBS (Gibco) parallel to 
using O-FBS (Stem Cell Technologies, Grenoble, 
France). Nonadherent cells were removed when the me-
dium was refreshed 5–7 days after the first seeding. Two 
different cell morphologies were observed according to 
the serum used to reconstitute the medium. Cells cul-
tured with FBS were irregular, with a large broad cyto-
plasm. Adherent cells cultured with O-FBS were exclu-
sively spindle shaped. The overall cell growth rates (de-
fined as the percentage of cell cultures continuing after 
the first medium refresh) were not different ( table  2 ). 
The medium with O-FBS yielded a higher number, 
showing cell growth after the first trypsinization (de-
fined as P0), reaching higher cumulative population 
doublings ( fig. 2 d). Secondary analysis by GA upon har-
vesting the initial AF sample showed better self-renewal 
properties prior to, rather than after, 20 weeks, as earlier 
described  [27] ( table 2 ).
 Flow Cytometry  
 Eighteen routine AF samples from the ‘prospective 
group’ were characterized at a mean population doubling 
of 12.7 ± 0.8. Again cells were positive for MSC markers 
CD29, CD44, CD73, CD105, and CD166 and negative for 
hematopoietic stem cell markers CD14, CD34, and CD45. 
Also AF-derived MSC showed a high percentage of posi-
tive cells for HLA-ABC (MHC I) combined with a low 
number of cells staining positive for HLA-DR (MHC II). 
There were no significant differences in surface markers 
between cells cultured with FBS and cells cultured with 
O-FBS. 
 Differentiation Ability and Karyotype 
 The prospective samples did not reach the required 
population doubling to determine their differentiation 
potential and their karyotype stability.
 Additional Improvement in Culture Conditions 
Using an Increased Initial Cell Density 
 A small percentage of the AF cell population had self-
renewal and differentiation abilities. Therefore, we decid-
ed to increase the cell density to 10 5 cells/cm 2 , the initial 
cell density seeded in parallel cultures using 27 prospec-
tive AF samples. The overall cell growth rates observed 
with both sera (FBS vs. O-FBS) were not significantly dif-
ferent (80.8 vs. 81.4%). These overall cell growth rates us-
ing a cell density of 10 5 cells/cm 2 were significantly high-
er than the cell growth rates observed in previous experi-
ments using a density of 10 3 cells/cm 2 combined with FBS 
or O-FBS (41.3 and 48.3%, respectively). Cells were char-
acterized using the same protocol as for the small-scale 
comparison. There were no significant differences in sur-
face markers. Cells cultured with both sera were positive 
for MSC markers CD29, CD44, CD73, CD105, and 
CD166 with a high percentage of positive cells for HLA-
ABC (MHC I) and a low number of cells staining positive 
for HLA-DR (MHC II). These cells were negative for he-
matopoietic stem cell markers CD14, CD34, and CD45. 
Cytogenetic analysis of AF cells prior to culturing and 
from cultures showed a normal karyotype. Differentia-
tion assays were performed but failed to show differentia-
tion abilities. 
Table 2.  Self-renewal ability according to the serum used for cul-
ture of amniotic cells obtained from pregnancies prior to or be-
yond 20 weeks of gestation
FBS O-FBS
Cell growth rate, % Overall 40.9 48.9
≤20 weeks 40.3 50.8
>20 weeks 42.3 46.1
Cell growth rate >P0, % Overall 69.4 90.7a
≤20 weeks 64.0 90.0a
>20 weeks 81.8 91.7
Cumulative PD Overall 10.0±1.5 15.9±1.5b
≤20 weeks 8.8±2.0 15.1±1.4b
>20 weeks 11.8±2.2 17.9±3.7
Maximum number Overall 1.4±0.2 2.7±0.3b
of passages ≤20 weeks 1.1±0.3 2.7±0.3b
>20 weeks 1.9±0.4 2.8±0.6
PDT, h Overall 168.2±27.0 170.6±24.7
≤20 weeks 211.7±53.7 117.8±74.5
>20 weeks 126.3±16.7 120.6±24.7
 Differences between media were only significant for the cell 
growth rate after the first trypsinization (P0), and population dou-
bling (PD) time (PDT) in the cells obtained prior to or at 20 weeks. 
a Significant difference, p < 0.05 (Fisher’s exact test). b Significant 
difference, p < 0.05 (Mann-Whitney U test).
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 Conclusion 
 Our study evaluated different culture conditions for 
isolation and characterization of AF-derived cells with 
mesenchymal features and self-renewal and differentia-
tion abilities. These culture conditions were previously 
reported for successful isolation of MSC and AF-derived 
cells. Although in vitro expansion of AF cells is possible, 
routine expansion in a prospective cohort in a setting 
mimicking what eventually may happen clinically was 
problematic. Though using different media and seeding 
of cells on gelatin-coated wells provided better results, the 
success rate (overall cell growth rate) remained below 
50% with a low initial cell density (10 3 cells/cm 2 ) protocol 
which was, again, considered clinically insufficient. In-
creasing the cell density to 10 5 /cm 2 at the first seeding 
resulted in a success rate of 81%, but differentiation assays 
failed to demonstrate multilineage potential. Therefore, 
culture of these cells remains a challenge, indicating the 
need for better culture media and conditions, which may 
be based on better characterization and selection of the 
initial cell population  [29, 39] .
 In our initial experiments, with media containing ei-
ther 2 or 10% FBS, the cell growth was similar until ap-
proximately 10 cell doublings. Thereafter, AF-derived 
cells grew better with a medium containing EGF, insulin, 
transferrin, and T3 besides 10% FBS (medium 2), and 
cell doubling times were independent of surface coat-
ings. The amount of FBS used in different studies about 
AF-MSC  [27–30, 39, 41] , amnion mesenchymal cells 
 [37] , and bone marrow-derived multipotent progenitor 
cells  [36] varied between 2 and 20%. Given these differ-
ences, the quoted self-renewal ability may not be com-
parable between different papers. Such differences are a 
common observation in publications about AF or pla-
centa-derived cells with mesenchymal features and self-
renewal and differentiation abilities. It reflects the het-
erogeneous methodologies used to isolate and to expand 
these cells and a lack of consensus about classification of 
the isolated cell population. An important improvement 
occurred in 2008 with the first international workshop 
about placenta-derived stem cells. A consensual classifi-
cation was published to standardize the methodologies 
used for placenta-derived MSC isolation. The minimal 
criteria for defining placenta-derived MSC were as fol-
lows: adherence to plastic; formation of fibroblast colo-
ny-forming units; a specific pattern of surface antigen 
expression (positivity for CD73, CD90, and CD105 and 
negativity for CD14, CD34, CD45, and HLA-DR), and 
differentiation potential toward one or more lineages, 
including osteogenic, adipogenic, chondrogenic, and 
vascular/endothelial. Surprisingly, this consensus did 
not included AF-derived cells  [31] . Recently, De Coppi 
et al.  [39] illustrated the heterogeneity of AF cell popula-
tions. They isolated a subgroup of AF-derived cells based 
on the expression of the surface antigen c-kit (CD117) 
and proposed to call these AF stem cells. They observed 
a remarkable cell self-renewal ability which had never 
been reported by others in the field, with up to >250 
population doublings obtained with a culture medium 
containing 15% of FBS. This is far superior to observa-
tions made in studies using adult MSC expanded up to 
30 population doublings in approximately 130–200 days 
 [42, 43] . Interestingly, Kim et al.  [41] described that AF-
MSC were able to undergo 66 population doublings over 
a time period of 8 months. In that study approximately 
40 cell doublings could be reached after 130 days of cell 
culture, implying a possible higher proliferative poten-
tial of fetal MSC compared to adult MSC, as described 
previously  [26, 28] . Kim et al.  [41] focused on the mo-
lecular profile and characterization of AF-derived stem 
cells, with less or no information about the number of 
AF samples, the cell density used to start the initial cul-
ture, and the observed cell growth rate compared to the 
number of processed samples. In the present study, we 
decided to highlight the influence of different culture 
conditions on the selection of a cell line with consistent 
self-renewal ability and differentiation properties in an 
initial small number of AF samples. Thereafter, we test-
ed our observations on a larger scale, a preliminary step 
that we considered an essential hurdle to overcome be-
fore further investigating this cell source for perinatal 
applications.
 The differentiation assays were set up after 20 cell dou-
blings. Osteogenic differentiation was possible but adipo-
genesis was not, although in previous studies successful 
differentiation was tested at earlier cell doublings show-
ing bilineage  [27, 28] , trilineage  [29, 30] , or even multi-
lineage  [39, 41] potential. Selection of a specific cell type 
through our isolation and expansion protocol may be a 
potential cause for this observed restriction in differen-
tiation ability. Bossolasco et al.  [30] suggested that their 
limited differentiation potential towards mesenchymal 
lineages could be due to cell heterogeneity with a high 
percentage of epithelial cells. During culture, bone mar-
row stromal cells progressively lose their adipogenic and 
chondrogenic differentiation potential. The adipogenic 
potential is apparently the first to be repressed, whereas 
the osteogenic and chondrogenic potentials proceed to-
gether, branching only very late, with the loss of chondro-
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genic differentiation ability after 22 cell doublings  [44] . 
Other authors have reported similar findings  [42, 45] .
 In the initial series, the culture condition with the best 
results was medium 2 combined with the gelatin coating. 
Our initially promising results were not confirmed when 
expanding on a larger scale in unselected AF samples, so 
that it was not possible to perform characterization, dif-
ferentiation, and karyotyping as scheduled. Therefore, we 
made two adjustments to our culture conditions. We test-
ed another FBS optimized for AF-MSC isolation and im-
proved our results. We finally tested a high initial cell 
density protocol with optimal cell self-renewal ability re-
sults. Cells isolated with these two culture condition im-
provements showed mesenchymal surface markers, but 
differentiation assays failed to show multilineage poten-
tial. Testing optimized FBS and the high initial cell den-
sity protocol with media 1 and 3 would certainly have 
been interesting, but we did not. The reason is that we 
consider the methodology described by De Coppi et al. 
 [39] to be the best available option for isolation and ex-
pansion of AF-derived stem cells. The disadvantages of 
commercial ready-to-use medium are the lack of compo-
sition control and that it may be difficult to use in clinical 
conditions (as most of the time it still contains bovine 
serum). The optimal AF-derived cell culture conditions 
need to be as simple as possible, with a minimal amount 
of compounds, and made without xenogeneic material. 
Such conditions should ideally be associated with mono-
clonal cell selection and expansion. Therefore, we have 
since moved on to protocols that expand clones of cells 
based on certain characteristics, such as c-kit expression 
 [39] .
 A limitation of the present study is that the effects of 
cytokines on cell proliferation and identification of pluri-
potency markers (Oct-4, Nanog, Sox2, SSEA3, and 
SSEA4) were not analyzed. This was not routinely done 
at the moment this study was designed. The cell popula-
tion we obtained in our study, though it showed some 
self-renewal ability and mesenchymal features (surface 
markers and unilineage differentiation ability), was dis-
tinct from amniocytes. However, those cells do not match 
the definition of an MSC or an AF stem cell. In summary, 
the conditions we used may have identified conditions 
where AF-derived mesenchymal progenitor cells could 
be cultured with reasonable efficacy, though the success 
rate and cell characteristics are not sufficient for a clini-
cally applicable harvesting program. However, we have 
not given up on the use of AF as a cell source and have 
moved on to more effective protocols  [46] . 
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